Evidence map›Paper›PMID 34979344›Full record

ArticleDiabetes & metabolic syndrome2022

The effect of obesity on in-hospital mortality among patients with COVID-19 receiving corticosteroids.

Matsuo So, Mai Takahashi, Yoshihisa Miyamoto, Yoshiko Ishisaka, Masao Iwagami, Yusuke Tsugawa, Natalia N Egorova, Toshiki Kuno

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & metabolic syndrome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Matsuo SoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, USA. Electronic address: so.matuo@gmail.com.
Mai TakahashiDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, USA. Electronic address: mai.takahashi@mountsinai.org.
Yoshihisa MiyamotoDivision of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan. Electronic address: ymiyamoto70@gmail.com.
Yoshiko IshisakaDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, USA. Electronic address: Ishisakayoshiko@gmail.com.
Masao IwagamiDepartment of Health Services Research, University of Tsukuba, Tsukuba, Japan. Electronic address: iwa1983@gmail.com.
Yusuke TsugawaDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA; Department of Health Policy and Management, UCLA Fielding School of Public Health, University of California, Los Angeles, USA. Electronic address: ytsugawa@mednet.ucla.edu.
Natalia N EgorovaDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: Natalia.egorova@mountsinai.org.
Toshiki KunoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, USA; Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, USA. Electronic address: tkuno@montefiore.org.
Mount Sinai Beth Israel · USIcahn School of Medicine at Mount Sinai · USUCLA Health · USUniversity of Tokyo Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsObesity has been reported to be one of the most frequent comorbidities in COVID-19 patients and associated with higher rates of in-hospital mortality compared to non-obese patients. Acute kidney injury (AKI) is also known to be a complication associated with obesity in critically-ill COVID-19 patients. We aimed to investigate whether obesity was associated with increased risk of in-hospital mortality and AKI among patients with COVID-19 treated with corticosteroids.

methodsWe utilized 9965 hospitalized COVID-19 patient data and divided patients who were treated with corticosteroids into 6 groups by body mass index (BMI) (less than 18.5, 18.5-25, 25-30, 30-35, 35-40, 40 kg/m

resultsThere were 4587 study participants receiving corticosteroids (mean age 66.5 ± 15.5 years, men 56.6%, mean BMI 29.0 ± 7.2 kg/m

conclusionsClass III obesity was associated with high in-hospital mortality and AKI in patients with COVID-19 treated by corticosteroids. Clinicians must stay vigilant on the impact of class III obesity and development of AKI to disease trajectory of COVID-19 patients.

Indexed as

COVID-19COVID-19 Drug TreatmentHospital MortalityObesityAdrenal Cortex HormonesAdultAgedAged, 80 and overBody Mass IndexComorbidityCritical IllnessFemaleHumansIncidenceMaleMiddle AgedAdrenal Cortex HormonesAcute kidney injuryCOVID-19MortalityObesity

Identifiers

PMID34979344
PMCPMC8714243
OpenAlexW4200288174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.